72 HAMMERSMITH ROAD, LONDON, X0
Silence Therapeutics Enters Open Market Sale Agreement with Jefferies
Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Investor Presentation
Appointment of Rhonda Hellums as Executive Director at Silence Therapeutics
Amended material disclosure
Announces Leadership Changes
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2023
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership